Paul Atkins Plans to Introduce SEC Innovation Exemptions This Year
SEC Chair Paul Atkins is pushing for innovation exemptions to ease regulations on Web3 firms, signaling a major shift in US crypto policy. While the proposal could boost innovation, it also raises concerns about financial risk and regulatory integrity.
At a recent event in Manhattan, SEC Chair Paul Atkins vowed to deliver innovation exemptions by the end of the year. This would give Web3 firms explicit permission to ignore certain regulations.
The Commission can’t make any progress on the effort right now, due to the government shutdown. It will need to carefully construct the exemptions’ language to retain crucial fiscal guardrails and prevent instability.
Innovation Exemptions Explained
Since Paul Atkins took over at the SEC in April, he’s been revolutionizing US crypto regulation in several key ways. Between his involvement in market structure legislation and moves to approve altcoin ETFs, he’s made a lot of progress, but there’s one immediate goal that remains out of reach.
For over a month, Atkins has been describing an “innovation exemption” for crypto firms. The rules are a little unclear, but they would essentially allow Web3 businesses to ignore existing rules.
The CFTC already experimented with this, declaring that it will take no action against Polymarket for previous violations. This allowed the platform to return to the US.
Atkins has repeatedly commented on the innovation exemption, claiming that he hopes to bring it about soon. Today, he made a public appearance with CFTC Commissioner Caroline Pham, where he explicitly stated that this rule change should take effect before 2026:
“I have confidence [that the SEC] will be able to do it. [The exemption] is one of the top priorities…because I want to be welcoming to innovators and have them feel like they can do something here in the United States,” Atkins reportedly told the attendees.
Is This a Good Idea?
He also addressed a few other topics, mentioning that all official SEC business is frozen as long as the US federal government remains shut down. Although individual employees are free to publicly advocate for future rules changes, the Commission won’t be preparing these innovation exemptions for the foreseeable future.
Still, if Atkins can enact innovation exemptions for crypto, it would represent a huge change. The Trump administration has been pursuing a laissez-faire regulatory attitude with the industry, but this would revolutionize things.
However, the SEC will need to craft the language of these measures carefully. “Crime is legal now” is a damaging ethos to the crypto community, and Atkins is proposing explicit permission to break the rules.
Without crucial guardrails, these radical measures may further destabilize capital markets.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"
Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.
Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business
Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
Crypto prices
More
